Genoray Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Genoray.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Medical Equipment earnings growth | 40.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Why Genoray's (KOSDAQ:122310) Shaky Earnings Are Just The Beginning Of Its Problems
Mar 28
Does Genoray Co., Ltd. (KOSDAQ:122310) Have A Place In Your Dividend Portfolio?
Apr 12Does Genoray (KOSDAQ:122310) Have A Healthy Balance Sheet?
Mar 01We Like Genoray's (KOSDAQ:122310) Returns And Here's How They're Trending
Feb 11
Is Genoray Co., Ltd.'s (KOSDAQ:122310) Recent Performance Tethered To Its Attractive Financial Prospects?
Jan 27Is Genoray Co., Ltd. (KOSDAQ:122310) A Smart Choice For Dividend Investors?
Jan 12Genoray Co., Ltd. (KOSDAQ:122310) Looks Interesting, And It's About To Pay A Dividend
Dec 24A Look At The Fair Value Of Genoray Co., Ltd. (KOSDAQ:122310)
Dec 15We Think Genoray (KOSDAQ:122310) Can Stay On Top Of Its Debt
Nov 30In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genoray has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 97,897 | 12,486 | -5,044 | 3,555 | N/A |
| 9/30/2023 | 92,300 | 12,794 | -12,765 | 3,170 | N/A |
| 6/30/2023 | 85,470 | 12,315 | -10,863 | 5,051 | N/A |
| 3/31/2023 | 83,225 | 12,945 | -1,344 | 13,170 | N/A |
| 12/31/2022 | 82,604 | 13,900 | 1,057 | 14,837 | N/A |
| 9/30/2022 | 83,336 | 14,874 | 15,209 | 21,454 | N/A |
| 6/30/2022 | 83,964 | 15,663 | 12,757 | 18,948 | N/A |
| 3/31/2022 | 78,643 | 14,745 | 9,234 | 16,289 | N/A |
| 12/31/2021 | 74,290 | 14,323 | 6,475 | 15,383 | N/A |
| 9/30/2021 | 64,502 | 11,057 | 3,695 | 11,903 | N/A |
| 6/30/2021 | 63,259 | 10,327 | 9,050 | 17,078 | N/A |
| 3/31/2021 | 62,145 | 10,007 | 4,675 | 11,571 | N/A |
| 12/31/2020 | 61,688 | 10,172 | 4,228 | 8,507 | N/A |
| 9/30/2020 | 67,862 | 13,260 | 5,177 | 9,567 | N/A |
| 6/30/2020 | 67,052 | 13,788 | 1,180 | 5,915 | N/A |
| 3/31/2020 | 66,469 | 14,142 | 5,679 | 10,566 | N/A |
| 12/31/2019 | 65,106 | 13,240 | 5,826 | 10,655 | N/A |
| 9/30/2019 | 59,345 | 11,859 | 3,448 | 8,047 | N/A |
| 6/30/2019 | 55,975 | 10,058 | 1,505 | 6,300 | N/A |
| 3/31/2019 | 56,567 | 9,659 | -14 | 4,688 | N/A |
| 12/31/2018 | 56,289 | 9,472 | 2,697 | 6,893 | N/A |
| 9/30/2018 | 53,189 | 8,323 | 1,513 | 5,697 | N/A |
| 6/30/2018 | 51,083 | 7,490 | 4,446 | 7,996 | N/A |
| 3/31/2018 | 46,055 | 5,741 | 3,396 | 6,450 | N/A |
| 12/31/2017 | 44,492 | 5,170 | 1,401 | 4,472 | N/A |
| 12/31/2016 | 38,278 | 3,225 | N/A | 3,473 | N/A |
| 12/31/2015 | 31,880 | 1,997 | N/A | 2,100 | N/A |
| 12/31/2014 | 28,569 | 956 | N/A | 3,272 | N/A |
| 12/31/2013 | 30,475 | 437 | N/A | 985 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if A122310's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if A122310's earnings are forecast to grow faster than the KR market
High Growth Earnings: Insufficient data to determine if A122310's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if A122310's revenue is forecast to grow faster than the KR market.
High Growth Revenue: Insufficient data to determine if A122310's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if A122310's Return on Equity is forecast to be high in 3 years time